Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
15 01 2020
Historique:
entrez: 17 1 2020
pubmed: 17 1 2020
medline: 30 1 2020
Statut: epublish

Résumé

To investigate the impact of modifications to contemporary cancer protocols, which minimize exposures to cardiotoxic treatments and preserve long term health, on serious cardiac outcomes among adult survivors of childhood cancer. Retrospective cohort study. 27 institutions participating in the Childhood Cancer Survivor Study. 23 462 five year survivors (6193 (26.4%) treated in the 1970s, 9363 (39.9%) treated in the 1980s, and 7906 (33.6%) treated in the 1990s) of leukemia, brain cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, renal tumors, neuroblastoma, soft tissue sarcomas, and bone sarcomas diagnosed prior to age 21 years between 1 January 1970 and 31 December 1999. Median age at diagnosis was 6.1 years (range 0-20.9) and 27.7 years (8.2-58.3) at last follow-up. A comparison group of 5057 siblings of cancer survivors were also included. Cumulative incidence and 95% confidence intervals of reported heart failure, coronary artery disease, valvular heart disease, pericardial disease, and arrhythmias by treatment decade. Events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events. Multivariable subdistribution hazard models were used to estimate hazard ratios by decade, and mediation analysis examined risks with and without exposure to cardiotoxic treatments. The 20 year cumulative incidence of heart failure (0.69% for those treated in the 1970s, 0.74% for those treated in the 1980s, 0.54% for those treated in the 1990s) and coronary artery disease (0.38%, 0.24%, 0.19%, respectively), decreased in more recent eras (P<0.01), though not for valvular disease (0.06%, 0.06%, 0.05%), pericardial disease (0.04%, 0.02%, 0.03%), or arrhythmias (0.08%, 0.09%, 0.13%). Compared with survivors with a diagnosis in the 1970s, the risk of heart failure, coronary artery disease, and valvular heart disease decreased in the 1980s and 1990s but only significantly for coronary artery disease (hazard ratio 0.65, 95% confidence interval 0.45 to 0.92 and 0.53, 0.36 to 0.77, respectively). The overall risk of coronary artery disease was attenuated by adjustment for cardiac radiation (0.90, 0.78 to 1.05), particularly among survivors of Hodgkin lymphoma (unadjusted for radiation: 0.77, 0.66 to 0.89; adjusted for radiation: 0.87, 0.69 to 1.10). Historical reductions in exposure to cardiac radiation have been associated with a reduced risk of coronary artery disease among adult survivors of childhood cancer. Additional follow-up is needed to investigate risk reductions for other cardiac outcomes. ClinicalTrials.gov NCT01120353.

Identifiants

pubmed: 31941657
doi: 10.1136/bmj.l6794
pmc: PMC7190022
doi:

Banques de données

ClinicalTrials.gov
['NCT01120353']

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

l6794

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA055727
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare support from the National Cancer Institute (CA55727, to GTA, principal investigator) for the Childhood Cancer Survivor Study; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Références

JAMA. 2013 Jun 12;309(22):2371-2381
pubmed: 23757085
J Clin Oncol. 1993 Jul;11(7):1208-15
pubmed: 8315419
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
J Clin Oncol. 2013 Oct 10;31(29):3673-80
pubmed: 24002505
Med Pediatr Oncol. 2002 Apr;38(4):229-39
pubmed: 11920786
BMJ. 2009 Dec 08;339:b4606
pubmed: 19996459
Cancer. 2014 Nov 15;120(22):3536-44
pubmed: 25041978
J Clin Oncol. 2014 Nov 10;32(32):3643-50
pubmed: 25311213
N Engl J Med. 2016 Mar 3;374(9):833-42
pubmed: 26761625
Pediatr Blood Cancer. 2012 Mar;58(3):334-43
pubmed: 22038641
Ann Intern Med. 2016 Jan 19;164(2):93-101
pubmed: 26747086
JAMA. 2012 Jun 27;307(24):2609-16
pubmed: 22735430
Radiat Res. 2006 Jul;166(1 Pt 2):141-57
pubmed: 16808603
J Clin Oncol. 2015 Nov 10;33(32):3774-80
pubmed: 26304888
N Engl J Med. 1996 Mar 21;334(12):745-51
pubmed: 8592547
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
JAMA. 2010 Jul 14;304(2):172-9
pubmed: 20628130
Circulation. 2016 Nov 15;134(20):1519-1531
pubmed: 27821538
J Am Heart Assoc. 2019 Jan 8;8(1):e009122
pubmed: 30595059
Lancet Oncol. 2018 Dec;19(12):1590-1601
pubmed: 30416076
J Clin Oncol. 2009 May 10;27(14):2308-18
pubmed: 19364948
Pediatr Blood Cancer. 2013 Jul;60(7):1083-94
pubmed: 23418018
J Clin Oncol. 2009 Mar 1;27(7):1007-13
pubmed: 19171716
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1705-1713
pubmed: 29167278
J Clin Oncol. 2012 May 1;30(13):1429-37
pubmed: 22473161
N Engl J Med. 2010 Sep 30;363(14):1324-34
pubmed: 20879881
N Engl J Med. 1999 Oct 14;341(16):1165-73
pubmed: 10519894

Auteurs

Daniel A Mulrooney (DA)

Division of Cancer Survivorship, Department of Oncology, St Jude Children's Research Hospital, MS 735, 262 Danny Thomas Place, Memphis, TN 38105, USA daniel.mulrooney@stjude.org.
Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Geehong Hyun (G)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Kirsten K Ness (KK)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Matthew J Ehrhardt (MJ)

Division of Cancer Survivorship, Department of Oncology, St Jude Children's Research Hospital, MS 735, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Yutaka Yasui (Y)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Daniel Duprez (D)

Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Rebecca M Howell (RM)

Department of Radiation Physics, University of Texas at MD Anderson Cancer Center, Houston, TX, USA.

Wendy M Leisenring (WM)

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Louis S Constine (LS)

Departments of Radiation Oncology and Pediatrics, James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

Emily Tonorezos (E)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Todd M Gibson (TM)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Leslie L Robison (LL)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Kevin C Oeffinger (KC)

Department of Medicine, Duke University, Durham, NC, USA.

Melissa M Hudson (MM)

Division of Cancer Survivorship, Department of Oncology, St Jude Children's Research Hospital, MS 735, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Gregory T Armstrong (GT)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH